Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist]] (1) ·
[[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (3) ·
[[:Category:Mast_cell_stabilizers|Mast cell stabilizer]] (1) ·
[[:Category:Ophthalmic_antihistamines|Ophthalmic antihistamine]] (1) ·
[[:Category:Statins|Statin]] (3)
None (2) ·
'"`UNIQ--vote-000003D1-QINU`"' SLCO1B1 polymorphism affects exposure but is most clinically actionable for simvastatin'"`UNIQ--ref-000003D2-QINU`"'. (1) ·
'"`UNIQ--vote-00001284-QINU`"' Systemic oral ketotifen (available outside US) has historical use for asthma adjunct therapy via the same dual mechanism, but oral use produces sedation and weight gain — the topical ophthalmic application largely avoids both'"`UNIQ--ref-00001285-QINU`"'. (1)
10-20 mg PO once daily in the evening (40 mg starting allowed for high CV risk) (1) ·
20 mg PO once daily with the evening meal; titrate to 40-80 mg/d (1) ·
40 mg PO once daily (10-20 mg in elderly, hepatic impairment, or strong drug interactions) (1) ·
Ophthalmic 1 drop in each eye every 8-12 hours (1)
Not meaningfully described for ophthalmic use'"`UNIQ--ref-00001287-QINU`"' (1) ·
~2 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect lasts 24 hours via target turnover'"`UNIQ--ref-0000017A-QINU`"' (1) ·
~2-3 hours (parent); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-000003D5-QINU`"' (1) ·
~2-4 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-00000807-QINU`"' (1)
<5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"' (1) ·
<5% (extensive hepatic first-pass; statin pharmacology is hepatocellular, not systemic)'"`UNIQ--ref-0000017B-QINU`"' (1) ·
Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"' (1) ·
~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' (1)
Generally considered safe (minimal systemic exposure).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3)
Showing below up to 4 results in range #1 to #4.


